Resources for your adult patients
ADEMPAS® (riociguat) Resources
Prescribing Information (United Kingdom) [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website
Indication
ADEMPAS is a member of a class of therapeutic agents called ‘soluble guanylate cyclase stimulators (sGC stimulators)’, and is used for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).1
In PAH, ADEMPAS is licenced as monotherapy or in combination with endothelin receptor antagonists (ERAs), for the treatment of adult patients with PAH with WHO functional class (FC) II to III, in order to improve exercise capacity.1
In paediatric patients aged less than 18 years of age and body weight ≥50 kg, ADEMPAS is licensed for the treatment of PAH in combination with ERAs for patients in WHO FC II to III.1
In CTEPH, ADEMPAS is licenced for the treatment of adult patients with WHO functional class II to III with:1
- inoperable CTEPH
- persistent or recurrent CTEPH after surgical treatment
to improve exercise capacity.
Please refer to the Summary of Product Characteristics for further information to minimise the risks associated with the use of ADEMPAS before making prescribing decisions.
Resources for your adult patients
Guide for adult patients who have been prescribed ADEMPAS for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH)
Guide for adult patients who have been prescribed ADEMPAS for the treatment of pulmonary arterial hypertension (PAH)
If you are initiating an eligible patient on ADEMPAS, we have the home monitoring pack service available to support. The home monitoring pack has been designed to help your patients as they start their treatment on ADEMPAS. This consists of a blood pressure monitor and associated items to help your patients monitor their blood pressure during the titration period.
The loan of the Blood Pressure equipment is supported by MSD UK Ltd. To order a home monitoring pack for your centre, please contact our third party supplier Uniphar Commercial (E4H) UK Limited using the following contact details:
Phone: 0800 012 6055
Email: hmp@hcpconnect-uniphar.com
Please be aware you should not direct your patient to this website. You should download this guide on their behalf and share it with them as appropriate.
Supporting documentation
Prescribing Information (United Kingdom) [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website
References
1. ADEMPAS 0.5 mg film-coated tablets. Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/5334/. Accessed: January 2025.
